Remedy Entertainment reported an operating loss of 2.9 million EUR and a net loss of 2.8 million EUR for the first half of 2026.
02
Q2 2026 revenue fell to 10.2 million EUR, representing a 40 percent year-over-year decline due to the absence of prior-year launch accruals and increased marketing spend for 'Control Resonant'.
03
The company maintains its full-year outlook for growth in revenue and EBITDA, anchored by the scheduled September 24, 2026, launch of 'Control Resonant'.
04
The balance sheet remains stable with an equity ratio of 65.3 percent and total assets valued at 85.1 million EUR.
05
As of June 30, 2026, the company holds 25.1 million EUR in capitalized development costs.
06
Strategic risks include the transition to a self-publishing model, which requires managing complex development schedules and the retention of specialized personnel.
Insights
01
Remedy Entertainment reported an operating loss of 2.9 million EUR and a net loss of 2.8 million EUR for the first half of 2026.
02
Q2 2026 revenue fell to 10.2 million EUR, representing a 40 percent year-over-year decline due to the absence of prior-year launch accruals and increased marketing spend for 'Control Resonant'.
03
The company maintains its full-year outlook for growth in revenue and EBITDA, anchored by the scheduled September 24, 2026, launch of 'Control Resonant'.
04
The balance sheet remains stable with an equity ratio of 65.3 percent and total assets valued at 85.1 million EUR.
05
As of June 30, 2026, the company holds 25.1 million EUR in capitalized development costs.
06
Strategic risks include the transition to a self-publishing model, which requires managing complex development schedules and the retention of specialized personnel.